Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
115.80 CHF | +0.35% | -4.46% | +12.43% |
Sep. 22 | Transcript : Medacta Group SA, Q2 2023 Earnings Call, Sep 22, 2023 | CI |
Sep. 22 | Medacta Group Reports Higher H1 Attributable Profit, Revenue | MT |
Sales 2023 * | 506 M 535 M 489 M | Sales 2024 * | 569 M 602 M 551 M | Capitalization | 2 388 M 2 524 M 2 309 M |
---|---|---|---|---|---|
Net income 2023 * | 65 M 69 M 63 M | Net income 2024 * | 79 M 84 M 76 M | EV / Sales 2023 * | 4,98x |
Net Debt 2023 * | 131 M 138 M 127 M | Net Debt 2024 * | 121 M 128 M 117 M | EV / Sales 2024 * | 4,41x |
P/E ratio 2023 * | 36,7x | P/E ratio 2024 * | 30,0x | Employees | - |
Yield 2023 * | 0,60% | Yield 2024 * | 0,75% | Free-Float | 30.13% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
1 day | +0.35% | ||
1 week | -4.46% | ||
1 month | -6.61% | ||
3 months | -4.93% | ||
6 months | +16.73% | ||
Current year | +12.43% |
1 week
113.60
120.60

1 month
113.60
130.00

Current year
95.40
130.00

1 year
76.70
130.00

3 years
75.50
173.00

5 years
39.80
173.00

10 years
39.80
173.00

Date | Price | Change | Volume |
---|---|---|---|
23-09-29 | 115.80 | +0.35% | 8,681 |
23-09-28 | 115.40 | +0.52% | 5,013 |
23-09-27 | 114.80 | -1.71% | 23,479 |
23-09-26 | 116.80 | -2.18% | 9,963 |
23-09-25 | 119.40 | -1.49% | 6,741 |
Delayed Quote Swiss Exchange, September 29, 2023 at 11:30 am EDT
More quotes
Medacta International SA is a Swiss-based company specialized in medical devices. The Company develops, manufactures and distributes orthopaedic and neurosurgical medical devices. The Company designs a number of products, such as hip products, including hip replacement, hip anatomy, hip diseases, and other products for the preparation of hip surgery; knee product, which encompasses knee anatomy, knee diseases, knee replacement, the stability of the knee and for the preparation of knee surgery; shoulder product, which includes shoulder anatomy, shoulder disease, shoulder replacement, and for the preparation of shoulder operation, and spine product, which includes products for spinal treatments, spinal anatomy and for surgery, among others. Additionally, the Company also offers training and support to healthcare professionals.
Calendar
2023-10-16
- Investor Meeting - Research Partners
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
119.64EUR
Average target price
129.78EUR
Spread / Average Target
+8.48%
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. (M$) | |
---|---|---|
+12.43% | 2 527 M $ | |
-27.55% | 246 M $ | |
-45.01% | 553 M $ | |
-41.37% | 319 M $ | |
+71.43% | 67 M $ | |
+10.92% | 2 869 M $ | |
-52.65% | 1 226 M $ | |
-5.95% | 454 M $ | |
-3.77% | 299 M $ | |
+7.96% | 52 M $ |